Pardes Biosciences, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 24.22 million compared to USD 14.33 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 1.6 a year ago. Diluted loss per share from continuing operations was USD 0.41 compared to USD 1.6 a year ago.

For the full year, the company reported net loss was USD 96.63 million compared to USD 38.52 million a year ago. Basic loss per share from continuing operations was USD 1.66 compared to USD 10.13 a year ago. Diluted loss per share from continuing operations was USD 1.66 compared to USD 10.13 a year ago.